Kornimate/medical-research-clean huggingface dataset:
radiographic findings and their temporal changes in covid-19 positive changes patients: a prospective study

Conditions: COVID

Summary: all patient irrespective of age with confirmed covid-19 admitted to hospital and who underwent chest radiograph will be enrolled in the study to find raduigraphic findings and their temporal changes in covid-19.

in this prospective trial the investigator will work on radiology findings and their temporal changes in covid-19 positive patients and who underwent chest radiograph will be enrolled in our study. patient selection will be consecutive in addition of age , gender and comorbid conditions clinical information will included travel,expose and contact history. all patients should be positive for covid-19 via laboratory testing with real time reverse transcriptase polymerase chain reaction(rrt-pcr) in addition, the number of rrt-pcr tests performed on each patient, on which test a positive result was found,and the number of days between symptomology onset and date of first positive test will be recorded. in view of the current dynamics, any other reliable diagnostic test(s) if added to the clinical protocol will also be considered for inclusion in this study. tabulation of radiographic findings for all consecutive x-rays will be done along with the temporal changes of these findings. further, the clinical findings with the outcomes(duration of hospital findings, ventilatory support and discharge/death).

Eligibility criteria:
inclusion criteria: 1.patients confirmed positive for covid-19 by rrt-pcr irrespective of age. exclusion criteria: 1.patients with flu like symptoms but negative for covid-19 by rrt-pcr.
association between methotrexate erythrocyte polyglutamate concentration and clinical response in rheumatoid arthritis patients treated with subcutaneous injectable methotrexate

Conditions: Rheumatoid Arthritis

Summary: methotrexate (mtx) is the first-line treatment of rheumatoid arthritis (ra). in case of mtx failure, it is discussed to start a biologic disease-modifying antirheumatic drug (bdmards) according to the latest european recommendations of the eular. before to add a biologic disease-modifying antirheumatic drug (bdmards), an objective estimation of mtx impregnation could be carried out by mtx polyglutamates (mtx-pg). in rheumatoid arthritis patients with active disease estimated by das28 (disease activity score 28)\> 3.2 insufficiently controlled by mtx subcutaneously and patients in remission obtained with a das 28 \<2.6 with methotrexate prescribed since more than 6 months at stable dose for at least 3 months, a concentration of mtx-pg will be achieved.

the assumption is the association between low methotrexate erythrocyte polyglutamate and low clinical response in rheumatoid arthritis patients treated with subcutaneous injectable methotrexate. adherence to mtx will be assessed by the compliance questionnaire rheumatology (cqr). measurement of this adherence could optimize mtx treatment prior to the use of biotherapy which is costly with a lower infectious tolerance. correlation between its concentration and compliance assessed by cqr questionnaire will be tested.

Eligibility criteria:
inclusion criteria: * age \> 18 years and have social security affiliation. * patients followed in the rheumatology department at the hospital of st etienne. * patients with rheumatoid arthritis and : * either rheumatoid arthritis patients in remission (das 28\<2.6) with mtx treatment for at least 6months, and with a stable dose for 3months. * or patients with a high disease activity rheumatoid arthritis activity (das 28\>3.2) with mtx treatment (≥ 15 mg/weeks), taking mtx treatment for at least 6months with a stable subcutaneous weekly mtx injection (≥ 15 mg/weeks) treatment during the previous 3 months. * signed informed consent. exclusion criteria: * patients treated with another conventional synthetic disease modifying anti-rheumatic drugs (csdmard) * another diagnostic than rheumatoid arthritis

Keywords: rheumatoid arthritis methotrexate erythrocyte polyglutamate compliance questionnaire rheumatology
therapeutic dance intervention for children with cerebral palsy

Conditions: Cerebral Palsy

Summary: children with cerebral palsy (cp) have motor impairments that make it challenging for them to participate in standard physical activity (pa) programs. there is a need to evaluate adapted pa programs for this population. dance can promote coordination, posture, muscle strength, motor learning, and executive functioning. this pilot study evaluated the feasibility and the effects of a new therapeutic ballet intervention specifically designed for children with cp on physiological and executive functions outcomes.

8 children with cp (9-14y/o; 75% female) participated in a six-week therapeutic ballet program. participants had body composition (dxa), muscle strength (hand-grip dynamometer), habitual physical activity, gait and selective motor control functions, and executive function tasks before and after the intervention. follow-up assessments of habitual physical activity, gait and executive functions were completed four to five week post-intervention.

Eligibility criteria:
inclusion criteria: * cerebral palsy spastic diplegia and/or hemiplegia * absence of health problems that would preclude participation in exercise * male or female age 9 - 15 years inclusive at the time of consent * minimum level of intellectual functioning (e.g., as determined by an iq score of 80 or above or other education placement and testing indicating sufficient understanding) * ability to complete study measures at the assessment * ability to participate in dance classes conducted in english * interest in learning ballet * intact vision * intact hearing * able to ambulate independently in the community with or without a device * intact proprioception in lower extremities * able to complete assessment measures and consents in english * referral from the child's pediatrician or other physician indicating that the child is physically able to participate in an exercise intervention exclusion criteria: * children with a current diagnosis of severe major depressive disorder * generalized anxiety disorder * epilepsy * autism * other major medical conditions that prohibit full participation and children with severe developmental disorders (e.g., mental retardation, severe autism) or with physical impairments that prohibit full participation were excluded from the study.
the posative study: study for the treatment of positional obstructive sleep apnea

Conditions: Sleep Apnea Syndromes

Summary: this study is a prospective, multi-center, randomized crossover of the nightbalance spt compared to apap for the treatment of positional obstructive sleep apnea (posa).

this study is a prospective, multi-center, randomized crossover of the nightbalance spt compared to apap for the treatment of posa. the primary objective of the study is to demonstrate non-inferiority of treatment with the spt as compared to apap.

Eligibility criteria:
inclusion criteria: 1. subject is between the ages of 20 and 80. 2. diagnosis of posa meeting all the following criteria per in-lab control psg (performed within 3 months of screening): * total ahi \>15, or ahi \>10 and \ 10 * supine ahi at least twice the non-supine ahi * non-supine ahi \<10 (\<5 in mild patients) * supine time \>40% and \<60% 3. subject understands the study protocol and is willing and able to comply with study requirements and sign informed consent. exclusion criteria: 1. prior surgery to treat osa (such as uppp), or prior or current therapy or treatment for osa, with the exception of pap being used for split night psg only. 2. a female of child-bearing potential that is pregnant or intends to become pregnant. 3. any unstable or severe medical condition of any organ system including congestive heart failure, copd, renal failure, neuromuscular disease, or at the discretion of the site principal investigator (pi). 4. taking medication that may affect sleep, sleepiness, or alertness including hypnotics, sedatives, alerting agents, stimulants, opiates, sedating antidepressants, and anticonvulsants. 5. oxygen use. 6. the presence of any other sleep disorder (central sleep apnea (csa \>5), periodic limb movement disorder (plmai \>15), clinical diagnosis of insomnia or narcolepsy). 7. excessive alcohol consumption (\>21 drinks/week). 8. the use of any illegal drug(s). 9. night or rotating shift work. 10. severe claustrophobia. 11. shoulder, neck, or back complaints that restrict sleeping position. 12. subject requires use of more than 2 pillows under the head while sleeping or sleeps in a bed/chair with raised upper body position.

Keywords: positional sleep apnea positional obstructive sleep apnea posa osa obstructive sleep apnea sleep apnea
intraperitoneal dexamethasone, dexmedetomidine, and dexamethasone-dexmedetomidine combination on postoperative nausea and vomiting after laparoscopic cholecystectomy

Conditions: Laparoscopic Cholecystectomy; Postoperative Nausea and Vomiting

Summary: nausea and vomiting are some of the most common complaints of patients after any anesthesia, which is often associated with postop-erative pain. the double-blind clinical trial study aimed to compare the prophylactic effect of dexamethasone and dexmedetomidine and their combination in reducing postoperative nausea and vomiting in patients undergoing laparoscopic cholecystectomy.


Eligibility criteria:
inclusion criteria: * patients aged from 20 - 50 years * asa i or ii * undergo laparoscopic cholecystectomy exclusion criteria: * patients with history of psychotic illnesses, * parkinson's disease * motion disorder * smoker * or history of chemotherapy
study to evaluate single inhaled doses of pt001, pt003, pt005 and pt001 plus pt005 in healthy subjects

Conditions: Healthy Volunteers

Summary: the purpose of this study is to evaluate the safety of a single dose of pt003 compared with single doses of pt001 and pt005, and compared with pt001 plus pt005 delivered together as two separate single doses in healthy subjects.


Eligibility criteria:
inclusion criteria: * provide signed written informed consent * 18-55 years of age * healthy subjects confirmed by medical history, physical examination, vital signs, pulmonary function tests, electrocardiogram and clinical laboratory tests * female subjects of child-bearing potential who are sexually active must be willing to undergo a pregnancy test and agree to use two forms of contraception * body mass index (bmi) between 18.5 and 30, inclusive * non-smokers for at least 6 months prior to screening * pulmonary function tests within normal limits * willing to remain at the study center for at least 12-24 hours on each test day * venous access in both arms to allow collection of numerous blood samples exclusion criteria: * women who are pregnant or lactating * clinically significant medical conditions * viral illness within the last 30 days * symptomatic prostatic hypertrophy or bladder neck obstruction * known narrow-angle glaucoma * history of bowel obstruction * clinically significant abnormal electrocardiogram * positive hepatitis b surface antigen or positive hepatitis c antibody * positive screening test for hiv antibodies * history of hypersensitivity to any beta2-agonists, anticholinergics, or any component of the mdi * known or suspected history of alcohol or drug abuse within the last 2-years * greater than normal alcohol consumption * ingestion of any poppy seeds within the 48 hours prior to the screening * ingestion of any poppy seeds within the 48 hours prior to, or any alcohol, xanthines or grapefruit-containing foods or beverages within the 24 hours prior to, or during, each confinement * positive breath alcohol result * positive urine drug screen * use of any beta2-agonists,or anticholinergics prior to the recruitment interview * lower respiratory tract infections requiring antibiotics in the previous 6 weeks * use of any other prescription medication * use of any over the counter product, herbal product, diet aid, hormone supplement * donation \> 450 ml of blood within 8 weeks of first treatment dose * clinically significant vital sign abnormality * clinically significant biochemical, hematological or urinalysis abnormality * affiliations with investigator site * treatment with investigational study drug or participation in another clinical trial or study within the last 30 days or 5 half lives prior to screening, whichever is longer

Keywords: healthy volunteers
histiocytosis in injecting drug users

Conditions: Histiocytosis

Summary: the goal of this observational study is to describe a new disease condition of histiocytosis related to injecting drug use, its preconditions, symptoms, signs, findings, and prognosis in a detailed and systematic patient series in one referral center. the main question\[s\] it aims to answer are: * to find specific histologic features in different tissues to help the differential diagnosis from other histiocytoses * to describe the value of chitotriosidase activity to screen this condition * to describe the value of various tissue biopsies in confirming the diagnosis * to describe the nature of polyvinylpyrrolidone accumulation in tissue macrophages by novel special microscopic techniques * to find new tandem mass spectrometry methodology to prove polyvinylpyrrolidone accumulation in macrophages * to show that polyvinylpyrrolidone treatment activates macrophages to histiocytes and causes povidone accumulation within the cells in in vitro experiments * to evaluate the pathology of macrophage activation to histiocytes by transcriptomics the patient history will be collected from the data produced by follow-up of cases followed up in a single center. a subgroup of participants will be given an opportunity to sign informed consent to give access to/donate blood and tissue samples to search for techniques to prove polyvinylpyrrolidone storage within histiocytes, and to search for transcriptomics signal(s) in histiocytes. researchers will compare blood and tissue samples from the biobank as controls.

we will search for comprehensive patient data (disease history, findings, complications, laboratory findings, histopathology, and imaging) from patient records of a single university hospital. coded histiocytosis-positive tissue samples will be compared to biobank samples from corresponding tissues from healthy and other other histiocytosis tissue samples to show polyvinylpyrrolidone storage with novel methodologies. in addition, if study participant who is followed up, signs informed consent, monocytes are separated from a blood sample, differentiated to macrophages, and exposed to polyvinylpyrrolidone. various novel methods will be utilized to explore polyvinylpyrrolidone within histiocytes.

Eligibility criteria:
inclusion criteria: * all identified adult patients in our records with a history of injecting drug use by dissolving tablets containing polyvinylpyrrolidone and (suspected) pvp-histiocytosis exclusion criteria: * other histiocytosis diagnosed by tissue samples and clinical information

Keywords: intravenous drug abuse polyvinylpyrrolidone pvp
lumbar paraspinal muscle fatty infilteration

Conditions: Muscle Weakness

Summary: introducing a unique clinical case of limb-girdle muscular dystrophy associated with lbp that was initially misdiagnosed as non-specific lbp

this case report describes the history, examination findings, and clinical reasoning used for a patient suffering from lbp as a chief complaint. a new sign appeared in mri, which prompted the author to change the diagnosis process from lower back pain to a mysterious neurological disease, the mri revealed widespread fat deposit in the lumbar paraspinal muscles. this mri sign prompted the authors to do more lab investigation, showing a notably elevated level of creatinine phosphokinase (906 u/l). further clinical examination revealed proximal muscle weakness, winging of scapula and bilateral lmn facial palsy. therefore, the patient was ultimately directed to a neurologist who confirmed the diagnosis of limb-girdle muscular dystrophy

Eligibility criteria:
inclusion criteria: * experiencing lower back stiffness and a dull back pain exclusion criteria: * diabetes, heart disease, or muscle disease. any history of previous falls, accidents, surgeries, hospitalizations, and he denied any significant past illnesses, or allergies.
safety of cultured autologous adult adipose derived mesenchymal stem cell intravenous infusion for cp

Conditions: Cerebral Palsy

Summary: this trial will study the safety and efficacy of intravenous infusion of cultured autologous adult adipose derived mesenchymal stem cells for the treatment of cerebral palsy

studies have shown that stem cell treatment is safe and efficacious for the treatment of cerebral palsy (cp). this patient funded trial aims to study the safety and efficacy of intravenous infusion of cultured autologous adult adipose derived mesenchymal stem cells (ad-mscs) for the treatment of cp. patients with cp will receive a single intravenous infusion of ad-mscs. the total dose will be 100 million cells. patients will be evaluated within one month pre treatment and at 1, 6, 12, 24, 36, and 48 months post treatment for safety and efficacy.

Eligibility criteria:
inclusion criteria: * diagnosis of cerebral palsy exclusion criteria: * active infection * active cancer * chronic multisystem organ failure * pregnancy * clinically significant abnormalities on pre-treatment laboratory evaluation * medical condition that would (based on the opinion of the investigator) compromise patient's safety * previous organ transplant * seizure disorder * hypersensitivity to sulfur

Keywords: cerebral palsy cp stem cell treatment
programme to optimise risk factors in patients waiting for coronary artery bypass surgery

Conditions: Coronary Artery Disease

Summary: the time spent waiting for heart surgery can be extremely stressful. this programme aims to address this by providing a home-based, nurse-led support and education programme. patients will be followed up in their own homes monthly by a cardiac nurse and given lifestyle advice and information to prepare them for surgery. this will be evaluated to test whether providing this support improves patients' anxiety and quality of life while they wait and also whether their blood pressure, weight and cholesterol are reduced and they have a smoother recovery as a consequence.

while waiting for coronary artery bypass graft (cabg) surgery many patients receive little if any medical and nursing input, at a time which is very stressful for them and their families. this randomised controlled trial will test whether a home-based, nurse-led support and education programme for patients waiting for such surgery can optimise mental and physical fitness and improve coronary heart disease risk factors by addressing anxiety, hypertension, obesity, diabetes and serum cholesterol in the waiting period. patients will be followed up in their own homes monthly by a cardiac nurse and given lifestyle advice and information to prepare them for surgery. primary outcome measurements will be anxiety, length of stay, blood pressure, cholesterol, blood glucose, smoking and body mass index. secondary outcomes will be quality of life, and post-operative complications. economic analysis and qualitative assessment of patients' opinion of the programme will also be performed.

Eligibility criteria:
inclusion criteria: * patients waiting for first time cardiac bypass surgery * able to read and understand english exclusion criteria: * patients living outside designated geographical area (\>1.5 hours drive from hospitals) * patients having surgery other than first time coronary artery bypass grafts * patients unable to read and understand english * patients with life-threatening significant non-cardiovascular disease e.g. cancer * all risk factors under control (blood pressure \<140 systolic and/or \< 90 diastolic and/or serum cholesterol \<5 mmol/l and/or blood glucose \< 7mmol/l and anxiety score \< 8 on the hospital anxiety and depression scale).

Keywords: coronary artery bypass surgery risk factors nurse-led secondary prevention prehabilitation waiting period
the effect of a once daily dose of atomoxetine (atx) on adhd-related insomnia in children and adolescents

Conditions: Attention Deficit Hyperactivity Disorder; Insomnia

Summary: this study is a single site, double-blind, randomized, placebo-controlled parallel group design. this study is designed to directly examine the efficacy of a single daily dose of atomoxetine taken in the morning in alleviating sleep initiation insomnia in children with adhd. primary outcome measures are sleep parameters, specifically mean sleep onset latency (time of onset to persistent sleep), as measured by actigraphy/sleep diary, and parent and child-reported evening settling difficulties, as measured on the evening subscale items of the parent and child versions of the dpremb-r. secondary outcome measures include: additional actigraphic sleep parameters (night wakings, sleep duration, and sleep efficiency), daytime sleepiness (pediatric daytime sleepiness scale, sleepiness visual analogue scale (vas), and morning behaviors on the dpremb-r); adhd symptom improvement (adhd-rs, parent version; provider-completed cgi); a neurocognitive measure of attention and impulsivity (cpt); executive functions (brown add scale for children) and functional outcomes/quality of life (chq).


Eligibility criteria:
inclusion criteria: subjects are children aged 6 through 17 years with dsm-iv criteria-defined adhd and sleep initiation insomnia. exclusion criteria: the sleep onset delay must not be exclusively related to direct or rebound effects of psychostimulant treatment. all subjects will be screened for primary sleep disorders with survey questionnaires (children's sleep habits questionnaire, cshq (12) and restless sleep questionnaire) (visit 1); subjects scoring above a pre-defined threshold for osa and/or rls/plmd symptoms will be excluded from the study. other exclusion criteria include iq \< 80 (wisc-iii screen at baseline), history of significant chronic medical illness (diabetes, severe asthma), co-morbid depression or other significant psychiatric co-morbidities (odd, ld not excluded; determined by screening with the diagnostic interview schedule for children (disc)), history of chronic use of sedating (eg, antihistamines) or alertness-enhancing (eg, caffeine) medications, history of conditions for which use of atomoxetine is contraindicated (eg, narrow angle glaucoma), use of other prescription medication for adhd and/or use of prescription/otc medication for sleep (eg, alpha agonists, hypnotics, melatonin, antihistamines) following the screening visit, and history of failure to respond to an adequate (defined as appropriate dose and adequate duration of therapy) previous trial of atomoxetine

Keywords: attention deficit hyperactivity disorder insomnia atomoxetine